Q-omics provides the consensus-scored SOX15 profile across patient tissues and cancer cell-line models. SOX15 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SOX15 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, SOX15 protein abundance shows 19,306 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where SOX15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOX15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOX15 survival associations across molecular data types. SOX15 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOX15 RNA expression–survival associations across cancer types. High SOX15 expression shows unfavorable associations in KIRC, CHOL, KICH and ACC, but favorable associations in UVM and UCS. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SOX15 RNA expression.
This table summarizes SOX15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SOX15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOX15 shows lower tumor expression in KIRC, KICH, THCA and UCEC and higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher SOX15 RNA expression in tumor versus normal tissue (log2 FC = +1.175, t-test p < 0.001).
This table shows molecular features associated with SOX15 in patient tissues and cancer cell lines. In patient samples, SOX15 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SOX15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
